Patents by Inventor Yin-Ling Lin

Yin-Ling Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV fusion polypeptides
    Patent number: 8216590
    Abstract: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: July 10, 2012
    Assignee: Novartis AG
    Inventors: Michael Houghton, Yin-Ling Lin, Angelica Medina-Selby, Doris Coit
  • Activation of HCV specific T cells
    Patent number: 8178086
    Abstract: Methods for activating HCV-specific T cells are described. The methods utilize one or more administrations of HCV protein compositions, followed by one or more administrations of a viral vector comprising a nucleic acid encoding a least one HCV epitope that is present in the first composition. The protein compositions can further comprise an immunostimulatory nucleic acid and or other adjuvants and immune stimulatory compounds.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: May 15, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Michael Houghton, Yin-Ling Lin
  • HCV FUSION POLYPEPTIDEDS
    Publication number: 20100092503
    Abstract: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV.
    Type: Application
    Filed: February 27, 2007
    Publication date: April 15, 2010
    Inventors: Michael Houghton, Yin-Ling Lin, Angelica Medina-Selby, Doris Coit
  • Activation of HCV Specefic T Cells
    Publication number: 20100034844
    Abstract: Methods for activating HCV-specific T cells are described. The methods utilize one or more administrations of HCV protein compositions, followed by one or more administrations of a viral vector comprising a nucleic acid encoding a least one HCV epitope that is present in the first composition. The protein compositions can further comprise an immunostimulatory nucleic acid and or other adjuvants and immune stimulatory compounds.
    Type: Application
    Filed: January 4, 2007
    Publication date: February 11, 2010
    Inventors: Michael Houghton, Yin-Ling Lin